ABSTRACT
Female breast cancer (BC) is the leading cause of cancer-related deaths worldwide with higher mortality rates and early onset in developing countries. The molecular basis of early disease onset is still elusive. We recruited 472 female breast cancer from two sub-Saharan African countries (Cameroon and Congo) between 2007 and 2018 and collected clinical data from these patients. To investigate the molecular drivers of early disease onset, we analyzed publicly available breast cancer molecular data from the cancer genome atlas (TCGA) and the gene expression omnibus (GEO) for copy number alteration, mutation and gene expression. Early BC onset (EOBRCA) (diagnosis before 45 years) was higher in African women compared with the TCGA cohort (51.7% vs 15.6%). The tumor grade, mitotic index, HER2 + phenotype, basal-like phenotype and ki67 were higher in EOBRCA for all cohorts. BC risk factors such as parity, breastfeeding early onset of menarche and use of hormonal contraceptives were significantly associated with EOBRCA (p < 0.05). EOBRCA was equally associated with copy number alterations in several oncogenes including CDH6 and FOXM1 and tumor suppressor including TGM3 and DMBT1 as well as higher TP53 mutation rates (OR: 2.93, p < 0.01). There was a significant enrichment of TGFß signaling in EOBRCA with TGM3 deletions, which was associated with high expression of all SMAD transcription factors as well as WNT ligands. The Frizzled receptors FZD1, FZD4 and FZD6 were significantly upregulated in EOBRCA, suggesting activation of non-canonical WNT signaling. Our data, suggest the implication of TGM3 deletion in early breast cancer onset. Further molecular investigations are warranted in African patients.
Subject(s)
Breast Neoplasms , Neoplasms , Female , Humans , Pregnancy , Breast Neoplasms/genetics , Calcium-Binding Proteins , Cohort Studies , DNA-Binding Proteins , Frizzled Receptors , Mutation , Phenotype , Transglutaminases , Tumor Suppressor Proteins , AdultABSTRACT
Contexte et Objectif. Déterminer l'infl uence des toxicités hématologiques induites par la chimiothérapie sur l'adhésion à une chimiothérapie anticancéreuse chez des patients traités pour un cancer à l'hôpital universitaire Yalgado Ouédraogo (Ouagadougou, Burkina Faso). Méthodes. Il s'est agi d'une étude rétrospective ayant analysé les dossiers médicaux des patients cancéreux suivis par le service de cancérologie du CHU-YO. Tous les adultes ayant reçu six séances d'une première ligne de chimiothérapie ont été inclus. Pour chaque patient, nous avons analysé toutes les numérations formule sanguines effectuées environ 16 à 18 jours après la cure de chimiothérapie précédente et 3 à 5 jours avant la suivante. Ont été considérés comme observants, les patients ayant respecté tous les intervalles inter-cures. Résultats. Vingt-six patients (27,6%) ont présenté au moins un épisode d'anémie, 46 patients (48,9%) ont au moins un épisode de neutropénie et 9 patients (9,6%) ont au moins un épisode de thrombopénie. Les neutropénies de grade 3 et 4 représentaient de 67,9% à 87% des cas de neutropénie. Aucun cas de thrombopénie de grade 3 ou 4 n'a été observé. Vingt-deux patients ont respecté tous les intervalles intercures. Après ajustement sur les autres toxicités hématologiques en analyse multivariée, la neutropénie était associée de manière signifi cative au non-respect de la chimiothérapie (OR: 0,43). Conclusion. L'amélioration de la disponibilité et de l'accessibilité des moyens de prévention et de traitement des toxicités hématologiques pourraient permettre une amélioration de l'observance de la chimiothérapie anticancéreuse.
Aim and Objective. This study aims to identify the infl uence of chemotherapy induced haematological toxicities on adherence to anti-cancer chemotherapy in patients treated for cancer at Yalgado Ouédraogo University Hospital (Ouagadougou, Burkina Faso). Methods. This study was grounded on the analysis of the medical fi les of the patients, and the consultation and hospitalisation registers for the cancer patients who were monitored by the oncology department of CHU-YO. All adults having received six treatment sessions as fi rst-line chemotherapy were taken into account. For each patient, we analysed all the blood counts carried out approximately 16 to 18 days after the previous treatment session, and 3 to 5 days before the following one. Were considered adherent patients, the patients who complied with every intertreatment interval. Results. 26 patients (27.6%) presented with at least one episode of anaemia, 46 patients (48.9%) with at least one episode of neutropenia, and 9 patients (9.6%) with at least one episode of thrombocytopenia. Grade 3 and grade 4 neutropenia represented from 67.9% to 87% of neutropenia cases. No case of grade 3 and grade 4 thrombocytopenia was noticed. Twenty-two patients respected all the inter-treatment intervals. Adjusted on the other haematological toxicities as a multivariate analysis, neutropenia was significantly associated to non-adherence to chemotherapy (OR: 0.43). Conclusion. Improving availability and access to prevention and treatment for haematological toxicities could lead to improving adherence to anti-cancer chemotherapy
Subject(s)
Antineoplastic Combined Chemotherapy Protocols , Toxicity Tests , HematologyABSTRACT
Kidney cancer is the third most frequent urologic cancer. Metastases usually occur in the lung, the bone and the liver. We here report a clinical case of cutaneous and sinus metastases revealing kidney cancer in a 70 year old man.
Subject(s)
Carcinoma, Renal Cell/diagnosis , Kidney Neoplasms/diagnosis , Paranasal Sinus Neoplasms/secondary , Skin Neoplasms/secondary , Aged , Carcinoma, Renal Cell/pathology , Humans , Kidney Neoplasms/pathology , Male , Paranasal Sinus Neoplasms/pathology , Skin Neoplasms/pathology , Sphenoid Sinus/pathologyABSTRACT
Secondary metastatic cutaneous plasmacytoma is a multiple extramedullary plasma cell proliferation involving skin. Its diagnosis is based on the identification of malignant plasma cells proliferation in the bone marrow and in the skin. Its occurrence is associated with advanced myeloma and a poor prognosis.
